Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8WZA1

UPID:
PMGT1_HUMAN

ALTERNATIVE NAMES:
UDP-GlcNAc:alpha-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I.2

ALTERNATIVE UPACC:
Q8WZA1; D3DQ16; Q5VST2; Q5VST3; Q9BV55; Q9H9L8; Q9NXF9; Q9NYF7

BACKGROUND:
The enzyme Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 is pivotal in the biosynthesis of glycoproteins, specifically in the addition of N-acetylglucosamine to O-linked mannose. This process is critical for the proper function of alpha-dystroglycan and other O-mannosylated proteins, influencing cellular communication and structural integrity.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in a spectrum of muscular dystrophies and retinal diseases, targeting this protein could offer new avenues for therapeutic intervention. Its role in disease pathogenesis underscores the potential for developing targeted treatments that could ameliorate or even prevent these debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.